cilastatin--imipenem-drug-combination and Pulmonary-Disease--Chronic-Obstructive

cilastatin--imipenem-drug-combination has been researched along with Pulmonary-Disease--Chronic-Obstructive* in 2 studies

Other Studies

2 other study(ies) available for cilastatin--imipenem-drug-combination and Pulmonary-Disease--Chronic-Obstructive

ArticleYear
[A community acquired pneumonia case caused by Ralstonia pickettii].
    Mikrobiyoloji bulteni, 2009, Volume: 43, Issue:2

    Ralstonia pickettii, formerly known as Burkholderia pickettii, is a non-fermentative gram-negative bacillus. It is emerging as an opportunistic pathogen both in the hospital setting and in the environment, leading to outbreaks especially in the intensive care units. The available literature revealed two case reports of pneumonia associated with R. pickettii in adults. In this report, a case of pneumoniae due to R. pickettii, in a patient with chronic obstructive pulmonary disease was presented. Fifty-six years old male patient was admitted to the hospital with complaints of shortness of breath, cough, purulent sputum, weakness, fatigue and green colorred diarrhea lacking blood. Lung auscultation revealed decreased respiratory sounds in the right lower lobe. Laboratory findings yielded decreased arterial pH and paO2 and increased pCO2 values, while hemoglobin, hematocrite, blood urea and creatinine levels were increased. Chest X-ray showed an infiltration on right lower zone. The patient was intubated and imipenem 1 x 500 mg/day and netilmicin 1 x 80 mg/day were initiated. Deep tracheal aspirate specimen revealed gram-negative rods and leukocytes, and cultures yielded growth of non-fermentative gram-negative bacilli on blood agar and EMB agar. These bacilli were identified as R. pickettii by using VITEK 2 system (bi-oMerieux Inc, Mercy L'etoil, France). Antibiotic sensitivity test performed by VITEK 2 GP system (bioMerieux Inc, Mercy L'etoil, France) revealed sensitivity to ceftriaxone, imipenem/cilastatin, piperacillin/tazobactam, amikacin, gentamicin, cefoperazone-sulbactam and ciprofloxacin. Treatment with imipenem/cilastatin was continued for 14 days and the patient was completely recovered. This case was presented in order to call attention to R. pickettii as a pathogen that may cause community-acquired lower respiratory tract infection.

    Topics: Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Community-Acquired Infections; Drug Combinations; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; Protease Inhibitors; Pulmonary Disease, Chronic Obstructive; Ralstonia pickettii; Treatment Outcome

2009
Imipenem/cilastatin as monotherapy in the treatment of acute or chronic lung infections: clinical efficacy and safety.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Acute Disease; Adult; Aged; Bacterial Infections; Chronic Disease; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Humans; Imipenem; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia; Pulmonary Disease, Chronic Obstructive; Safety

1989